gene deficiencies, each causing impaired Th17 immune responses without directly affecting Th1-dependent immunity. These knockout mice, compared with their wild-type littermates, were much less susceptible to various murine models of crescentic glomerulonephritis (15, 20, 30, 31, 33, 36, 37, 40) . In particular, Gan et al. (15) recently demonstrated that IL-17-deficient mice were largely protected from anti-myeloperoxidase antibody-induced (anti-MPO) glomerulonephritis, a murine mimic of human anti-neutrophil cytoplasmic antibodyassociated glomerulonephritis (ANCA-GN), indicating that the pathogenesis of this model critically depends on IL-17. However, the study by Gan et al. (15) left the question open as to which cell types contribute to the production of IL-17 within the kidneys of these mice (12) . This is of great interest since recent studies (3-5, 7, 10, 11, 17, 23, 26, 27, 35, 38, 39) indicate that both in rodents and in humans the spectrum of cell types that are capable of contributing IL-17 is wider than previously thought: IL-17 can be produced not only by Th17 cells, but also by other, particularly innate immune cell types, including ␥␦T cells, iNKT cells, lymphoid tissue inducer cells, mast cells, and neutrophils. In human ANCA-associated vasculitis, serum IL-17 and IL-23 levels and circulating autoantigen-specific Th17 cells are elevated (1, 29) . However, the renal expression of IL-17 in human ANCA-GN still needs clarification (12, 20, 40) .
Therefore, the present study addresses the questions: is IL-17 expression detectable in kidneys of patients with acute ANCA-GN? Which cellular sources of IL-17 can be identified, and how are they distributed in the renal tissue?
PATIENTS, MATERIALS, AND METHODS
Patients and specimens. The study was conducted in accordance with the ethical principles stated by the Declaration of Helsinki and with approval obtained from the local ethics committee. Twenty-two patients were included who presented with their first manifestation of ANCA-positive rapidly progressive glomerulonephritis during the years 2009 to 2011. In all cases, the diagnosis of acute ANCA-GN was confirmed through biopsy evaluation in the Renal Pathology Unit at the University Medical Center Hamburg-Eppendorf. Kidney biopsies were fixed in neutral-buffered 4% formalin. Subsequently, the major portion of each biopsy specimen was embedded in paraffin and microtomized in 2-m sections following standard protocols. Periodic acid-Schiff, Masson-Goldner trichrome, and Giemsa stains were applied for light microscopic examination, as was the APAAP method for immunohistochemical detection of a standard panel of immunoglobulins and complement components (IgA, IgG, IgM, C1q, and C3c). A smaller portion of each biopsy was separately processed and embedded in epoxide resin (Araldite), and ultra-thin sections were examined by electron microscopy. The morphological findings of ANCA-GN were classified according to the scheme elaborated by Berden et al. (2) . Patients with preexisting significant renal disease or patients whose biopsies revealed significant glomerular or tubulointerstitial damage not attributable to ANCA-GN were not included in the study.
Immunohistochemistry and immunofluorescence. Two-micrometer sections of formalin-fixed paraffin-embedded tissue specimens were mounted on SuperFrost-plus glass slides (Menzel, Braunschweig, Germany), dewaxed, rehydrated, and pretreated with either Target Retrieval Solution pH 9 (Dako, Hamburg, Germany) or 10 mM citrate buffer pH 6.1 for 15 min at 90°C in a steamer (MultiGourmet, Braun, Kronberg, Germany) and then blocked 30 min in PBS containing 5% normal horse serum (Vector, Peterborough, UK) and probed with primary antibodies (as described below) at 4°C for 16 h.
Enzymatic immunohistochemical detection was achieved by antirabbit IgG secondary antibody-alkaline phosphatase complexes (POLAP, Zytomed, Berlin, Germany; or Vectastain ABC:AP, Vector) according to the manufacturers' instructions with neufuchsin as red chromogenic substrate. Fluorescent detection was obtained by secondary incubation with donkey antisera specific against goat, rabbit, or mouse IgG coupled with either AlexaFluor-488 (Invitrogen, Darmstadt, Germany) or Cy3 (Jackson/Dianova, Hamburg, Germany; all 1:200; 2 h at 20°C). Nuclei were stained with either hematoxylin or DAPI (Sigma-Aldrich, Munich, Germany). Slides were coverslipped in Fluoromount-G (SouthernBiotech, Birmingham, AL). For cytoblock preparation, leukocytes were enriched from EDTA blood by dextran sedimentation and hypotonic lysis of red blood cells, resuspended in 1% low melting agarose (Serva, Heidelberg, Germany), fixed in neutral-buffered 4% formalin, and embedded in paraffin. Sections were cut and immunoflurescence-labeled as described above.
A Zeiss Axioplan 2 microscope (Carl Zeiss, Hamburg, Germany) was used for conventional and fluorescence microcopy. Representative micrographs were recorded using a Zeiss Axiocam HRc digital camera and AxioVision software.
Antibodies and peptides. Affinity-purified polyclonal goat antihuman IL-17 antiserum AF-317 (purchased from R&D Systems, Wiesbaden, Germany) was used to detect IL-17 in human tissue sections (2 g/ml for immunofluorescence; 0.25 g/ml or 1 g/ml for immunohistochemistry with POLAP or ABC:AP kits, respectively). A rabbit anti-goat IgG specific antiserum (Vector; 1:200; 1 h at 20°C) was used as a bridge in the immunohistochemical detection of IL-17. The specificity of the AF-317 antibody in detecting IL-17 was confirmed by probing adjacent sections either with equivalent concentrations of normal goat IgG (sc-2028; 2 g/ml; Santa Cruz, Heidelberg, Germany), or after preabsorbtion with recombinant human IL-17A protein (317-ILB; R&D Systems; 4 g/ml), or by immunofluorescent costaining with a mouse monoclonal anti-human IL-17 antibody on the same section (eBio64DEC17; 5 g/ml; eBioscience/NatuTec, Frankfurt, Germany; requiring 10 mM citrate buffer pH 6.1 for heat-induced epitope retrieval). Recombinant human IFN-␥ (PeproTech, Hamburg, Germany; 4 g/ml) was used as an unrelated protein in preabsorption experiments. Affinity-purified rabbit polyclonal antisera against human MPO (A0398 Isolation of blood neutrophils and T cells and neutrophil stimulation. Neutrophils were isolated from EDTA whole human blood by red blood cell sedimentation in 1% dextran, followed by FicollHypaque density gradient centrifugation and hypotonic erythrocyte lysis. T cells were isolated by anti-CD2 coated magnetic bead sorting (CD2 MicroBeads; Miltenyi Biotec, Bergisch Gladbach, Germany). Cell viability was ascertained to exceed 99% by trypan blue exclusion. The purity of either neutrophil or T-cell preparations respectively exceeded 98%, as ascertained by flow cytometry. IL-17 levels in whole cell lysates were measured by a specific ELISA according to the manufacturer's instructions (Quantikine human IL-17; R&D Systems).
Purified human neutrophils were incubated at a density of 3 ϫ 10 6 cells/ml in RPMI 1640 medium containing 0.25% BSA (Life Technologies, Grand Island, NY) at 37°C in a 5% CO 2 atmosphere for up to 20 h. For neutrophil activation, 50 ng/ml PMA or 1 M formylMet-Leu-Phe (fMLP; Sigma) were added to the medium. IL-17 levels in the supernatants were measured by the Quantikine human IL-17 ELISA (R&D Systems). Statistical analyses. Statistical differences between groups were assessed by the nonparametric Mann-Whitney U-test for two groups and the nonparametric Kruskal-Wallis test for more than two groups and by applying the Bonferroni-Dunn's correction method for post hoc multiple pair-wise comparisons. Spearman's rank correlation coefficient was calculated as an estimate for the degree of association between two variables. Significance was assumed at P Ͻ 0.05. GraphPad Prism 5 software was used (La Jolla, CA).
RESULTS
Clinical and pathological characteristics of ANCA-GN patients. All 22 patients of the study cohort underwent diagnostic kidney biopsy for rapidly progressive glomerulonephritis with positive ANCA titers. The biopsies were examined in our Renal Pathology Unit using light microscopy, immunohistochemistry, and electron microscopy. In all cases, this triple diagnostic evaluation revealed active necrotizing and crescentic glomerulonephritis of pauci-immune phenotype, thus establishing the diagnosis of acute ANCA-GN. Ten patients received intravenous high-dose steroids 1-3 days before the renal biopsy was obtained. Twelve patients had no immunosuppressive treatment before biopsy. These two groups were not significantly different in the distributions of gender, age, proteinuria at biopsy, serum creatinine at biopsy, the total numbers of glomeruli sectioned per biopsy, and the proportions of glomeruli showing fresh necrosis or cellular crescents. The clinical and morphological findings are detailed in Table 1 and  Table 2 , respectively.
Detection of IL-17 in kidney biopsies. We examined renal biopsies of 22 patients with acute ANCA-GN, which is histologically characterized by fresh glomerular capillary necroses and cellular crescents (illustrated in Fig. 1A ), as well as tubulointerstitial injury with inflammatory cell infiltrates (Fig.  1B) . Both in the affected glomeruli and in the tubulointersti-tium, we detected many IL-17-expressing (IL-17 ϩ ) cells by immunohistochemistry using the anti-human IL-17 affinitypurified goat antibody AF-317 ( Fig. 1, C and D) .
Quantitative assessments of glomerular, tubulointerstitial, and total frequencies of IL-17 ϩ cells are respectively shown in Fig. 1 , E-G. We did not find significant differences between the group of 12 patients who were untreated at the time of biopsy and the group of 10 patients who had received highdose steroids 1-3 days before biopsy ( Fig. 1 , E-G).
All biopsies contained certain amounts of IL-17
ϩ mononuclear cells in which, as expected, IL-17 was localized to the cytoplasm. Moreover, in all cases substantial amounts of IL-17 ϩ polymorphonuclear cells were present, exhibiting a granular cytoplasmic staining for IL-17, as illustrated in Fig. 1H signals were obtained with both these control approaches, as demonstrated in Fig. 2, A and B , confirming that AF-317 specifically recognized IL-17 in the tissue sections. This was further corroborated by immunofluorescent colocalization with another, mouse monoclonal anti-human IL-17 antibody (clone eBio64DEC17) producing virtually the same staining pattern as AF-317 (Fig. 2C) .
Phenotypic differentiation of IL-17-expressing cells. To find out which cell types express IL-17 in acute ANCA-GN, we performed dual-color immunofluorescence analyses of IL-17 and a panel of phenotypic cell markers. In line with the immunohistochemical detection of IL-17 in polymorphonuclear granulocytes as exemplified in Fig. 1H , IL-17 was colocalized with abundant myeloperoxidase-expressing (MPO ϩ ) neutrophils present in affected glomeruli and in the tubulointerstitium, as represented in Fig. 3A . In contrast, colocalization with CD3 revealed only small numbers of IL-17 ϩ T cells, as represented in Fig. 3B , and only a small fraction (Ͻ1%) of all CD3 ϩ T cells expressed IL-17. In addition, colocalization with mast cell-specific tryptase revealed moderate amounts of IL-17 ϩ mast cells in the tubulointerstitium (Fig. 3C) . However, IL-17 ϩ T cells or mast cells were not found within glomeruli. Although MPO is highly enriched in neutrophils and widely used as marker to identify neutrophils by immunohistochemistry or immunofluorescence, MPO is also expressed in the monocyte-macrophage lineage. For this reason, we tested whether IL-17 could be detected in macrophages by colocalization with two highly specific and sensitive macrophage markers, CD68 (monoclonal antibody clone PG-M1) and CD163. While both these markers revealed numerous macrophages in ANCA-GN biopsies, they were not colocalized with IL-17, as respectively shown in Fig. 4, A and B . Hence, the IL-17
ϩ MPO ϩ cells observed in the present study (as shown in Fig. 3A) were neutrophils, whereas IL-17 expression was not detected in CD68 ϩ or CD163 ϩ macrophages (Fig. 4, A and  B) . In contrast to the macrophage-specific CD68 antibody clone PG-M1, another commonly used monoclonal CD68 antibody clone KP1 is not specific to macrophages but also , preabsorption with IL-17 protein almost completely abolished the immunoreactivity of AF-317. Nuclei were stained with DAPI (blue). C: dual-color immunofluorescence using AF-317 (red signals, left) and another, mouse monoclonal anti-human IL-17 antibody clone eBio64DEC17 (green signals, middle) on sections of a formalin-fixed paraffin-embedded human tonsil. Nuclei were stained with DAPI (blue). Staining patterns of both antibodies were largely congruent, as visualized by the yellow merge of the red and green signals (right). Altogether, these findings demonstrate that IL-17 was specifically recognized by the AF-317 antibody in immunohistochemical and immunofluorescent stainings of human tissues. labels mast cells and was therefore partially colocalized with IL-17 (Fig. 4, C-E mast cells, and these differences were statistically significant in both the untreated and the steroid-treated patients (P Ͻ 0.01), as presented in Fig. 5, A and B. IL-17 ϩ mast cells were more abundant than IL-17 ϩ T cells, but this difference was significant only when untreated and treated patients were pooled. IL-17 ϩ cell type-specific frequencies did not significantly differ between untreated and treated patients (Fig. 5, A and B) .
Correlation of IL-17-expressing neutrophils and T cells with serum creatinine levels.
Testing for potential associations of renal IL-17-producing cells with clinical parameters revealed a significant positive correlation between serum creatinine levels and total tubulointerstitial IL-17 ϩ cell frequencies in the untreated patient group (Spearman's rank correlation coefficient r ϭ 0.68; P ϭ 0.015) but not in the treated group (data not shown). To find out which IL-17 ϩ cell types accounted for this overall correlation in the untreated group, we performed separate analyses for neutrophils, T cells, and mast cells, and we found that IL-17 ϩ neutrophils (Spearman r ϭ 0.74; P ϭ 0.006) and IL-17 ϩ T cells (Spearman r ϭ 0.69; P ϭ 0.014) were both significantly correlated with creatinine, as, respectively, shown in Fig. 5 , C and D, whereas mast cells were not (data not shown).
Neutrophil IL-17 expression and release. To test whether IL-17 is expressed in circulating human neutrophils, we immunostained IL-17 in leukocyte preparations from healthy donor blood. Figure 6A shows that in these samples IL-17 was indeed detected in MPO ϩ neutrophils. To quantify the content of IL-17 protein in human neutrophils and T cells, we isolated these cell populations from the blood of healthy volunteers (n ϭ 4) and determined IL-17 protein levels in whole cell lysates by ELISA. As demonstrated in Fig. 6 , B and C, respectively, these neutrophil and T-cell preparations were at least 98% pure. Under basal conditions, 10 6 neutrophils contained significantly more IL-17 than 10 6 T cells (Fig. 6D) . To assess whether IL-17 may be actively secreted by neutrophils, we stimulated purified human neutrophils with PMA or fMLP in vitro and determined the levels of IL-17 protein in the supernatants. The results indicate that human neutrophils can release IL-17 in an activation-dependent manner (Fig. 6E) .
DISCUSSION
The present study is the first to address the question as to which cell types contribute to the production of IL-17 within the human kidney in the acute stage of ANCA-GN (12) . Our quantitative immunohistological data demonstrate that IL-17 is expressed by inflammatory cells in the glomeruli and tubulointerstitium of human kidneys with acute ANCA-GN and that, unexpectedly, the majority of these IL-17-expressing cells are neutrophils, whereas T cells and mast cells expressing IL-17 are significantly less abundant (Fig. 5, A and B) . These results suggest that, at least in ANCA-GN, IL-17 originating from innate immune cells, notably neutrophils and to a lesser extent also mast cells, may have a greater influence on the initiation and maintenance of renal inflammation than has so far been assumed.
Despite the fact that the identification and characterization of the Th17/IL-17 immune response have substantially improved our understanding of the pathogenesis of autoimmunity, there is a growing body of evidence that the spectrum of IL-17-producing cell types within inflamed tissues is wider than previously thought (7) . Only low numbers of IL-17-producing T cells were observed in immunohistochemical studies on Crohn's disease, psoriasis, lupus nephritis, and kidney allograft rejection (6, 8, 13, 25) . More recent reports (3, 4, 11, 17, 23, 27) have convincingly demonstrated the presence of abundant IL-17-expressing neutrophils and mast cells, but relatively few IL-17-expressing T cells, in inflamed human tissues such as synovial membrane, skin, lung, and atherosclerotic plaques.
Further specific cell types of the murine as well as human innate immune system have recently been identified as potent early producers of IL-17, including ␥␦T cells, iNKT cells, and lymphoid tissue inducer cells (5, 26, 38, 39) . These innate immune cells reside preferentially at the host-environment interfaces of the skin and mucous membranes, where they incite a rapid immune response against potential pathogens (7). Neutrophils, in contrast, are the most abundant and ubiquitous innate cell type, which are rapidly recruited as a first line of defense against invading organisms. In the pathogenesis of ANCA-GN, neutrophils are the first-line effectors of acute vasculitic injury (19) .
A single study by Dragon et al. (9) has provided evidence that human neutrophils constitutively express the IL-17 receptor IL-17RA. Therefore, it cannot be completely ruled out that the detection of IL-17 in neutrophils by us and others (3, 4, 11, 23, 27) could be due to an internalization of receptor-bound IL-17 from the cell surface into the cytoplasm. Speaking against this, however, are 1) the absence of a surface membrane staining pattern, which should at least be detectable to a similar degree as the granular cytoplasmic staining (Fig. 1H) if surface ligand-receptor complexes were internalized; 2) the expectation that receptor-mediated internalization would result in clearance rather than intracellular accumulation of the ligand (14, 28) ; and 3) the evidence that neutrophils can actively release IL-17, as provided by our human data (Fig. 6E) and by previous mouse studies (10, 16, 22, 24, 34, 41) .
Our finding that human neutrophils can release IL-17 is in agreement with recent experimental work (22) demonstrating that neutrophils are a crucial source of IL-17 during the pathogenesis of acute ischemia and reperfusion injury in the mouse kidney. Moreover, murine neutrophils have been shown to release IL-17 in vitro upon stimulation with anti-MPO antibodies (16) . Since IL-17 knockout mice were largely protected from anti-MPO glomerulonephritis (15) , it is tempting to speculate whether the pathogenesis of this ANCA-GN-like model may depend on the release of IL-17 from anti-MPO antibody-activated neutrophils. This, however, needs to be clarified by future experiments. In vitro, IL-17 stimulated human umbilical vein endothelial cells to express the neutrophil-attracting chemokines CXCL1, CXCL2, and CXCL8 (data not shown). Hypothetically, direct delivery of IL-17 from neutrophils to endothelial cells, which might take place in vivo as suggested by Fig. 1H , might upregulate endothelial expression of these neutrophil-attracting chemokines and might eventually result in an amplification loop able to sustain the vasculitic inflammatory process. The potential clinical importance of renal IL-17-producing neutrophils is further supported by a correlation with serum creatinine levels in untreated ANCA-GN patients (Fig. 5C) .
It remains to be determined which stimuli prompt neutrophils to release IL-17 in vivo and whether neutrophils or their precursors require IL-23 receptor activation and the transcription factor ROR␥t to express IL-17, as do Th17 cells and certain cells of the innate immune system (7). In the latter cell types, IL-17 secretion may be inhibited through agents that block IL-23 signaling. If neutrophils, in contrast, could release IL-17 in an IL-23-independent manner, our data would implicate that therapeutic approaches of inhibiting the IL-23 pathway might be less effective than directly targeting IL-17. The low proportion of IL-17 ϩ T cells out of all CD3 ϩ T cells that we observed in the ANCA-GN biopsies is in line with previous human studies (1, 18) on circulating blood T cells in granulomatosis with polyangiitis (formerly called Wegener's), psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. Particularly, as demonstrated by Abdulahad et al. (1) , the population of CD4 ϩ CD69 ϩ T cells isolated from ANCApositive patients' blood contained on average Ͻ3% IL-17-producing Th17 cells even after PMA/ionomycin stimulation in vitro. However, we would like to emphasize that IL-17 ϩ T cells (although at low numbers) are clearly present in the inflamed kidney (Fig. 3B) and are significantly correlated with renal function as reflected by serum creatinine levels in untreated ANCA-GN patients (Fig. 5D) . This underscores the pathogenic capacity of "classic" Th17 cells.
In conclusion, our data substantially enhance the knowledge of the cellular origin of IL-17 in human ANCA-GN and might therefore advance the general understanding of the role of IL-17 in inflammatory tissue injury and its dynamics. This might be critical for the development of IL-17-targeted strategies to treat renal and probably also systemic ANCA-associated vasculitis and perhaps even other autoimmune and inflammatory disorders.
